Samstag, 31. Juli 2021
Navigation öffnen

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma



Juni 2020

Letztes Update:

AMG 910

Indikation (Clinical Trials):
Adenocarcinoma, Esophageal Neoplasms


Erwachsene (18+)

Phase 1




Study Director


(3 von 18)

Universitaetsklinikum Hamburg Eppendorf Onkologisches Zentrum
20246 Hamburg
GermanyRekrutierend» Google-Maps
Gynäkologisches Tumorzentrum am Universitätsklinikum Leipzig
4103 Leipzig
DeutschlandRekrutierend» Google-Maps
Darmkrebszentrum am Klinikum der Universität München Campus Großhadern
Marchioninistraße 15
81377 München
DeutschlandRekrutierend» Google-Maps
Pankreaskrebszentrum am Klinikum rechts der Isar
Ismaninger Straße 22
81675 München
DeutschlandRekrutierend» Google-Maps
City of Hope National Medical Center
91010 Duarte
United StatesRekrutierend» Google-Maps
University of California at Irvine Medical Center
92868 Orange
United StatesRekrutierend» Google-Maps
Wake Forest Baptist Health
27157 Winston-Salem
United StatesRekrutierend» Google-Maps
Aichi Cancer Center Hospital
464-8681 Nagoya-shi
JapanRekrutierend» Google-Maps
National Cancer Center Hospital East
277-8577 Kashiwa-shi
JapanRekrutierend» Google-Maps
National Cancer Center Hospital
104-0045 Chuo-ku
JapanRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Severance Hospital Yonsei University Health System
03722 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Asan Medical Center
05505 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Samsung Medical Center
06351 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Amsterdam UMC - location VUmc
1081HV Amsterdam
NetherlandsRekrutierend» Google-Maps
Hospital Universitari Vall d Hebron
08035 Barcelona
SpainRekrutierend» Google-Maps
Alle anzeigen


Brief Summary:

To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the

maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)


Inclusion Criteria:

- Subjects with histologically or cytologically confirmed metastatic or locally advanced

unresectable gastric or GEJ adenocarcinoma positive for CLDN18.2.

- Subjects should not be eligible for curative surgery and should have been refractory

to or have relapsed after two or more prior lines of standard systemic therapy that

included a platinum, a fluoropyrimidine, either a taxane or irinotecan, and an

approved vascular endothelial growth factor receptor (VEGFR) antibody/tyrosine kinase

inhibitor (TKI) and depending on country-specific standards and approvals.

- For subjects eligible for human epidermal growth factor receptor 2 (HER2) directed

therapy, prior systemic therapy should have included a HER2 targeting antibody

approved for treatment of gastric cancer.

- Subjects may also be included if the aforementioned therapeutic options were medically

not appropriate for them. In these cases, the reason(s) why required prior therapies

for gastric cancer were medically not appropriate should be documented in the

subject's electronic case report form (eCRF).

- For dose-expansion only: Subjects with at least 1 measurable lesion greater than or

equal to 10mm which has not undergone biopsy within 3 months of screening scan. This

lesion cannot be biopsied at any time during the study.

- Subjects with stable condition and anti-coagulative therapy ongoing for at least 1

month, no obvious signs and symptoms of bleeding, and coagulation parameters are


- Subjects should be able to use proton pump inhibitors.

Exclusion Criteria:

- Any anticancer therapy or immunotherapy within 4 weeks of start of first dose (14 days

for palliative radiation).

- Untreated or symptomatic central nervous system (CNS) metastases, leptomeningeal

disease, or spinal cord compression

- Autoimmune disorders requiring chronic systemic steroid therapy or any other form of

immunosuppressive therapy while on study, eg, ulcerative colitis, Crohn's disease, or

any other gastrointestinal autoimmune disorder causing chronic nausea, vomiting, or

diarrhea. Recent or current use of inhaled steroids or physiological substitution in

case of adrenal insufficiency is not exclusionary.

- Evidence or history within last 3 months of gastrointestinal inflammatory conditions

not associated with the underlying cancer disease including gastrinomas, duodenitis,

proven gastric ulcer, duodenal ulcer, pancreatitis, or subjects with recent gastric

bleeding. Subjects may be included if the symptomatic/immunosuppressive treatment is

discontinued more than 4 weeks prior to the first dose of AMG 910, symptoms have

resolved, and gastroscopy does not indicate signs of active disease.

- Subjects with inherited bleeding disorders (eg, Willebrand's disease, hemophilia A and

other clotting factor deficiency) and subjects with known heparin-induced


- Subjects requiring non-steroidal anti-inflammatory drugs (NSAIDs) during study

treatment. The NSAID(s) should be stopped within 7 days prior to start of treatment.


Primary outcome:

1. Number of participants with dose-limiting toxicities (DLT) (Time Frame - 2 years):
Subject grade of dose limiting toxicities is the occurrence of any of the toxicities during the DLT evaluation period if judged by the investigator to be related to the administration of AMG 910

2. Number of participants with treatment-emergent adverse events (Time Frame - 2 years)

3. Number of participants with treatment-related adverse events (Time Frame - 2 years)

4. Number of participants with clinically significant changes in vital signs (Time Frame - 2 years)

5. Number of participants with clinically significant changes in electrocardiogram (ECG) (Time Frame - 2 years)

6. Number of participants with clinically significant changes in clinical laboratory tests (Time Frame - 2 years)

Secondary outcome:

1. Maximum serum concentration (Cmax) (Time Frame - 2 years)

2. Minimum serum concentration (Cmin) (Time Frame - 2 years)

3. Area under the concentration-time curve (AUC) over the dosing interval (Time Frame - 2 years)

4. AUC accumulation following multiple dosing (Time Frame - 2 years)

5. Half-life (t1/2) (Time Frame - 2 years)

6. Objective response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST (Time Frame - 2 years)

7. Duration of response (DOR) (Time Frame - 2 years)

8. Time to progression (Time Frame - 2 years)

9. Progression-free survival (PFS) (Time Frame - 6 months and 1 year)

10. Overall survival (OS) (Time Frame - 1 year and 2 years)


  • Experimental: Dose-exploration
    The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 910 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
  • Experimental: Dose-expansion
    The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.

Geprüfte Regime

  • AMG 910:
    Dose Exploration Dose Expansion


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose